Pharmacological management of behavioral disturbance in dementia

P and T

Volumn 32, Issue 10, 2007, Pages 560-566

  Casey, David A ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZATROPINE MESILATE; CHLORPHENIRAMINE MALEATE; CHLORPROMAZINE; CHLORZOXAZONE; CHOLINESTERASE INHIBITOR; CYPROHEPTADINE; DICYCLOVERINE; DIPHENHYDRAMINE; DONEPEZIL; DOXEPIN; GALANTAMINE; GLYCOPYRRONIUM BROMIDE; HYDROXYZINE EMBONATE; HYOSCYAMINE SULFATE; IMIPRAMINE; MEMANTINE; METAXALONE; NEUROLEPTIC AGENT; OLANZAPINE; OXYBUTYNIN; PROPANTHELINE BROMIDE; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; THIORIDAZINE; TOLTERODINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BEHAVIOR DISORDER; BIPOLAR DEPRESSION; DEMENTIA; DISEASE SEVERITY; DRUG EFFICACY; HALLUCINATION; HUMAN; PARKINSONISM; POLYPHARMACY; REVIEW; SYMPTOM; SYMPTOMATOLOGY; TREATMENT OUTCOME;

EID: 35948964484     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Alzheimer's Disease Facts and Figures. Washington, DC: Alzheimer's Association; March 2007.
2. Cummings JL. Neuropsychiatric and behavioral alterations and their management in moderate to severe Alzheimer's disease. Neurology 2005;65 (6 Suppl 3):S18-S24.
3. Burke JR, Morgenlander JC. Managing common behavioral problems in dementia: How to improve quality of life for patients and families. Postgrad Med 1999;106(5):131-140.
4. Lyketsos CG, Steinberg M, Tschanz JT, et al. Mental and behavioral disturbances in dementia: Findings for the Cache County Study on Memory in Aging. Am J Psychiatry 2000;157(5):708-714.
5. Maher RL. The pharmacological approach of behavioral disturbances in dementia. J Pharmacy Pract 2004;17(2):129-132.
6. Kim SY, McCallum C, Tariot PN, et al. What do people at risk for Alzheimer disease think about surrogate consent for research? Neurology 2005;65(9):1395-1401.
7. Cummings JL, McRae T, Zhang R. Effects of donepezil on neuropsychiatric symptoms patients with dementia and severe behavioral disorders. Am J Geriatr Psychiatry 2006;14:605-612.
8. Cummings JL, Schneider E, Tariot PN, et al. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology 2006;67(1):57-63.
9. Street J, Mitan S, Tamura R, et al. Olanzapine in the treatment of psychosis and behavioral disturbances associated with Alzheimer's disease. Eur J Neurol 1998;5(Suppl):39.
10. Katz IR, Jeste DV, Mintzer JE, et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: A randomized, double-blind trial. J Clin Psychiatry 1999;60:107-115.
11. Tariot PN, Salzman C, Yeung PP, et al. Long-term use of quetiapine in elderly patients with psychotic disorders. Clin Ther 2000;22:1068-1084.
12. Tariot PN, Profenno LA, Ismail MS. Efficacy of atypical antipsychotics in elderly patients with dementia. J Clin Psychiatry 2004;65(Suppl)11:11- 15.
13. Sink KM, Holden KF, Yaffe K. Pharmacologic treatment of neuropsychiatric symptoms of dementia: A review of the evidence. JAMA 2005;293:596-608.
14. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: Meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 2006;14 (3):191-210.
15. Schneider LS, Tariot PN, Dagerman KS, et al., the CATIE-AD Study Group. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 2006;355(15):1525-1538.
16. FDA Public Health Advisory: Deaths with antipsychotics in elderly patients with behavioral disturbances, April 11, 2005. Available at: www.fda.gov/cder/drug/advisory/antipsychotics.htm.
17. Brodaty H, Snowdon AD, Woodward M, et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry 2003;64(2):134-143.
18. Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 2005;353(22):2335-2341.
19. Tariot PN, Raman R, Jakimovich L, et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer's disease complicated by agitation: A randomized, controlled trial. Am J Geriatr Psychiatry 2005;13(11):942-949.
20. Lonergan ET, Cameron M, Luxenberg J. Valproic acid for agitation in dementia. Cochrane Database Syst Rev 2004;(2):CD003945.
21. Porsteinsson AP. Divalproex sodium for the treatment of behavioural problems associated with dementia in the elderly. Drugs Aging 2006;23(11):877-886.
22. Alexopolous GS, Jeste DV, Chung H, et al. The Expert Consensus Guideline Series. Treatment of dementia and its behavioral disturbances. Introduction: Methods, commentary, and summary. Postgrad Med 2005; No. 6-22.
23. Pollock BG, Mulsant BH, Sweet R, et al. An open pilot study of Citalopram for behavioral disturbances of dementia: Plasma levels and real time observations. Am J Geriatr Psychiatry 1997;5:70-78.
24. Pollock BG, Mulsant BH, Rosen J, et al. Comparison of Citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry 2002;159(3):460-465.
25. Begunovic OJ, Greenfield SF. Practical geriatrics: Use of benzodiazepines among elderly patients. Psychiatr Serv 2004;55(3):233-235.
26. Alisky JM. Lorazepam reversible catatonia in the elderly can mimic dementia, coma and stroke. Age Ageing 2007;36(2):229.
27. Singer C, Bahr A. Assessing and treating sleep disturbances in patients with Alzheimer's disease. Psychiatric Times 2007;22(13).
28. Ancoli-Israel S, Alessi C. Sleep and aging. Am J Geriatr Psychiatry 2005;13:341-343.